Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Busse

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Clinical Therapeutics|December 16, 2004
Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group studyWilliam Busse, Bernard Levine, Kim Andriano, et al.
The Journal of Allergy and Clinical Immunology|April 18, 2013
High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effectsWilliam Busse, Sheldon Spector, Karin Rosén, et al.
The Journal of Allergy and Clinical Immunology|January 15, 2019
ReplyNecdet B Gunsoy, Daniel J Bratton, Frank C Albers, et al.
American Journal of Respiratory and Critical Care Medicine|June 25, 2004
Future research directions in asthma: an NHLBI Working Group reportWilliam Busse, Susan Banks-Schlegel, Patricia Noel, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2010
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthmaMarc Massanari, Harold Nelson, Thomas Casale, et al.
The Journal of Allergy and Clinical Immunology|February 28, 2012
Omalizumab and the risk of malignancy: results from a pooled analysisWilliam Busse, Roland Buhl, Carlos Fernandez Vidaurre, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 13, 2014
Omalizumab in asthma: an update on recent developmentsMarc Humbert, William Busse, Nicola A Hanania, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 12, 2022
Insights from the AUSTRI study on reliever use before and after asthma exacerbationsWilliam Busse, David Stempel, Bhumika Aggarwal, et al.
The Journal of Allergy and Clinical Immunology|September 12, 2018
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparisonWilliam Busse, Geoffrey Chupp, Hiroyuki Nagase, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2016
A randomized multicenter study evaluating Xolair persistence of response after long-term therapyDennis Ledford, William Busse, Benjamin Trzaskoma, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Clinical Therapeutics|December 16, 2004
Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group studyWilliam Busse, Bernard Levine, Kim Andriano, et al.
The Journal of Allergy and Clinical Immunology|April 18, 2013
High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effectsWilliam Busse, Sheldon Spector, Karin Rosén, et al.
The Journal of Allergy and Clinical Immunology|January 15, 2019
ReplyNecdet B Gunsoy, Daniel J Bratton, Frank C Albers, et al.
American Journal of Respiratory and Critical Care Medicine|June 25, 2004
Future research directions in asthma: an NHLBI Working Group reportWilliam Busse, Susan Banks-Schlegel, Patricia Noel, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2010
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthmaMarc Massanari, Harold Nelson, Thomas Casale, et al.
The Journal of Allergy and Clinical Immunology|February 28, 2012
Omalizumab and the risk of malignancy: results from a pooled analysisWilliam Busse, Roland Buhl, Carlos Fernandez Vidaurre, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 13, 2014
Omalizumab in asthma: an update on recent developmentsMarc Humbert, William Busse, Nicola A Hanania, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 12, 2022
Insights from the AUSTRI study on reliever use before and after asthma exacerbationsWilliam Busse, David Stempel, Bhumika Aggarwal, et al.
The Journal of Allergy and Clinical Immunology|September 12, 2018
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparisonWilliam Busse, Geoffrey Chupp, Hiroyuki Nagase, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2016
A randomized multicenter study evaluating Xolair persistence of response after long-term therapyDennis Ledford, William Busse, Benjamin Trzaskoma, et al.
Pageof 5